Brief: Erasca Achieves Key Milestones For Naporafenib And ERAS-801 Programs And Extends Cash Runway

Erasca

28/11/2023 15:07

Nov 28 (Reuters) - Erasca Inc  ERAS.O :
    * ERASCA ACHIEVES KEY MILESTONES FOR NAPORAFENIB AND
ERAS-801
PROGRAMS AND EXTENDS CASH RUNWAY
    * ERASCA INC: EXTENDED CASH RUNWAY TO H1 2026 FOLLOWING
STRATEGIC
PRIORITIZATION OF PROGRAMS
    * ERASCA INC: DOSING OF FIRST PATIENT IN PIVOTAL PHASE 3
SEACRAFT-2 TRIAL IN PATIENTS WITH NRASM MELANOMA EXPECTED H1
2024
    * ERASCA INC: FLAGSHP-1 - PHASE 1B COMBINATION TRIAL OF
ERAS-601
SHP2 INHIBITOR WITH CETUXIMAB WAS DEPRIORITIZED
    * ERASCA INC: ERAS-5 - PRECLINICAL ULK INHIBITOR  ERAS-10
AND 
PRECLINICAL PROTEIN DEGRADER WERE ALSO DEPRIORITIZED

Source text for Eikon:  ID:nGNXbyxxsC 
Further company coverage:  ERAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))